Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bristol-Myers Squibb Plans Layoffs In 2017

As Bristol-Myers Squibb’s HIV drugs Reyataz and Sustiva lose patent protection, the company plans to lay off 58 staffers in October 2017.

Read More »

2017 Annual Report – Top 200 Medicines: Humira Remains Atop The Throne

AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.

Read More »

FDA Approves Vectibix For Use In Wild-Type RAS Metastatic Colorectal Cancer

Amgen announced that the U.S. FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS metastatic colorectal cancer.

Read More »

Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration

Array BioPharma and Bristol-Myers Squibb announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array’s investigational MEK inhibitor binimetinib in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.

Read More »

Array BioPharma, Merck Strategic Collaboration

Array BioPharma entered into a clinical trial collaboration with Merck to study a novel drug combo for colorectal cancer patients with microsatellite stable tumors.

Read More »

FDA approves Bayer’s Stivarga to treat most common liver cancer

The U.S. Food and Drug Administration said it approved Bayer AG’s drug Stivarga to treat liver cancer, the first such approval in nearly a decade.

Read More »

Chi-Med Shows Off Phase III Cancer Drug Data

Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.

Read More »

Bayer applies for Regorafenib authorization to treat liver cancer

German drugmaker Bayer said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.

Read More »

Bristol-Myers to test Opdivo with Nektar drug

Bristol-Myers Squibb will evaluate the use of its blockbuster immunotherapy Opdivo with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Read More »

2016 Annual Report: Top 200 Medicines

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom